Objective To investigate the effects of tanshinone IIA sulfonate sodium injection on the urinary N-ace-tyl-β-D-glucosidase（NAG）

β2-microglobulin（β2-MG）

serum procollagen type I carboxy-terminal propeptide（PICP）

and podocyte marker protein podocalyxin（PCX） levels in patients with hypertensive complicatedby kid-ney injury. Methods Ninety-four patients with hypertension complicated by kidney injury admitted to a hospital in Shenyang from January 2017 to June 2019 were selected for the study

and the patients were divided into ob-servation and control groups using the randomized grouping method

with 47 cases in each group. Patients in the control group were given irbesartan（150 mg/d） orally

and patients in the observation group were given tanshi-none IIA sulfonate sodium injection（50 mg/d） intravenously on the basis of the treatment in the control group for a total of 8 weeks. The blood pressure

serum PICP and PCX levels

serum urea nitrogen and creatinine lev-els

urinary NAG

β

2

-MG

and microalbumin（m ALB） levels of the two groups were compared before and after treatment

and the occurrence of adverse reactions was compared between the two groups. Results Before treat-ment

there were no statistically significant differences in systolic and diastolic blood pressure

serum urea nitro-gen and creatinine levels

serum PICP and PCX levels

and serum urinary m ALB

NAG

and β

2

-MG levels be-tween the two groups（P

>

0.05）. After treatment

the systolic and diastolic blood pressure

serum urea nitro-gen and creatinine levels

serum PICP and PCX levels

serum urinary m ALB

NAG

and β

2

-MG levels were sig-nificantly lower than those before treatment in both groups

and those in the observation group were significantly lower than the control group（P

<

0.05）. In the control group

8 cases of adverse reactions occurred during the treatment

and the incidence of adverse reactions was 17.02%; in the observation group

4 cases of adverse reac-tions occurred during the treatment

and the incidence of adverse reactions was 8.51%; the incidence of adverse reactions between the two groups（χ

2

=1.528

P=0.216）. Conclusion Tanshinone IIA sodium sulfonate com-bined with irbesartan can effectively reduce blood pressure and the levels of kidney injury markers in serum and urine among patients with hypertensive complicated by kidney injury and improve their renal function with few ad-verse reactions. Therefore

it is worthy of clinical promotion and application.